Linked Life Data

9498677

Source:http://linkedlifedata.com/resource/pubmed/id/9498677

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1998-3-31
pubmed:abstractText
Tiagabine x HCl is being developed as an anti-convulsant/anti-epileptic agent for seizure disorders. The pharmacological activity of the R-(-)-enantiomer is higher than that of the S-(+)-enantiomer. Therefore, the drug is synthesized in the pure R-(-)-enantiomeric form. The enantiomers of tiagabine x HCl were separated on a modified cellulose stationary phase (Chiralcel-OD) with a mobile phase of hexane-isopropanol-ethanol (80:14:06, v/v/v). Approximately 5 ml of trifluoroacetic acid was added for each liter of the mobile phase mixture. The method is capable of separating the two enantiomers with a selectivity factor of 1.55 and a resolution factor of 3.4. The samples of tiagabine x HCl were monitored by a UV detector at 260 nm. The method was validated by conducting standard addition and recovery of the S-(+)-enantiomer in tiagabine x HCl. The R.S.D. of the method is 3.2%. The limit of quantification (LOQ) of the S-(+)-enantiomer present in tiagabine x HCl is about 0.03%.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1387-2273
pubmed:author
pubmed:issnType
Print
pubmed:day
23
pubmed:volume
705
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
111-7
pubmed:dateRevised
2000-12-18
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Separation and quantitation of the S-(+)-enantiomer in the bulk drug tiagabine x HCl by chiral high-performance-liquid chromatography using a Chiralcel-OD column.
pubmed:affiliation
Department 41G, Bioanalytical Research, Abbott Laboratories, North Chicago, IL 60064, USA.
pubmed:publicationType
Journal Article